Dopamine receptor type 2 (D2R) and somatostatin receptor (SSTR) expression have been demonstrated in both gonadotroph and hormone-negative adenomas, prompting the investigation of dopamine agonists and somatostatin analogs as potential treatment strategies (41–43). This evidence concerns the gene DRD2 and adenoma.